Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: A Systematic Review for the U.S. Preventive Services Task Force [Internet]. From ACC / AHA, 2018. 199 Dosages shown are total daily dosages; exceptions are noted.

High-intensity statin therapy Moderate-intensity statin therapy Prescription Rosuvastatin 20-40 mg Simvastatin 80 mg Ezetimbe-simvastatin 80 mg Sitagliptin-simvastatin 20-40 mg Pravastatin 40—80 mg Lovastatln 40 mg Niacin-lovastatin 40 mg Fluvastatin XL 80 mg Fluvastatin 40 mg bid Pitavastatin 2—4 mg Atorvastatln 40—80 mg

Jul 1, 2023 · For example, 10 or 20 mg of atorvastatin daily is considered moderate intensity, while 40 to 80 mg is high intensity. The choice of a statin depends on a person's risk. For someone with high LDL but no other risk factors or evidence of coronary artery disease, moderate-intensity therapy makes sense.

May 1, 2019 · • Maximally tolerated statin therapy is recommended for patients 20 to 75 years of age with an LDL-C level of 190 mg per dL or greater. • Moderate-intensity statin therapy should be initiated...

Note: The shading reflects doses listed in the ACC/AHA Guideline on Treatment of Blood Cholesterol (2013) as reflecting high-intensity therapy (≥ 50% reduction in LDL-C, darker shading) and moderate-intensity therapy (30% to 50% reduction in LDL-C, lighter shading).

Aug 23, 2022 · The USPSTF also recommended that clinicians may choose to offer a low- to moderate-dose statin to adults without a history of CVD who meet criteria 1 and 2 above and have a calculated 10-year risk of a cardiovascular event of 7.5% to less than 10%.

Jan 15, 2017 · The USPSTF recommends that adults without a history of cardiovascular disease (CVD) (i.e., symptomatic coronary artery disease or ischemic stroke) use a low- to moderate-dose statin for the...

Apr 15, 2021 · Strong evidence supports moderate-dose statins as the best therapy in primary prevention for patients at elevated risk, with relative risk reductions in cardiovascular events and mortality of...

a 10-year ASCVD risk of ≥7.5%, start a moderate-intensity statin if a discussion of treatment options favors statin therapy. - if at a 10-year risk of 7.5%-19.9% (intermediate risk), risk-enhancing factors* favor initiation of statin therapy. • Assess adherence and percentage response to LDL-C–lowering medications and lifestyle changes

Clinical Review Report: Icosapent Ethyl (Vascepa): (HLS Therapeutics Inc.): Indication: Prevention of cardiovascular events in statin-treated patients [Internet]. b.i.d. = twice daily; LDL-c = low-density lipoprotein cholesterol. Copyright © 2020 Canadian Agency for Drugs and Technologies in Health.